[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Squawk Box @SquawkCNBC on x 513.7K followers
Created: 2025-07-25 12:05:35 UTC
Goldman Sachs biotech analyst Salveen Richter breaks down the latest troubles surrounding $SRPT’s drug Elevidys and where the company can go from here:
XXXXX engagements
Related Topics $srpts goldman sachs stocks financial services